Law, Judgments & Legal Insights.

Decade-Long Silence: Bombay HC Stays "Sleeping" Regulatory Demands

In a significant ruling concerning the limits of regulatory oversight, the Bombay High Court has quashed a series of demands issued by the Union of India against pharmaceutical manufacturer Tridoss Laboratories Pvt. Ltd. . The court ruled that the government’s decade-long delay in calling upon a private entity to justify alleged drug overcharging constitutes a flagrant violation of the principles of natural justice.

The Disputed Decade

The dispute originated from the manufacture of Phylobid CR 300 mg (Theophylline), a controlled drug formulation. The petitioner discontinued this product in 2006. Nearly a decade later, in 2015 and 2016, the National Pharmaceutical Pricing Authority (NPPA) issued notices alleging that the petitioner had overcharged consumers and mandated the recovery of over one crore rupees. When the company failed to pay, the Tahsildar issued a recovery notice under the Maharashtra Land Revenue Code, threatening the attachment of property.

The core legal question was whether a regulatory body can initiate recovery proceedings more than ten years after the alleged event, particularly when such delay renders the accused unable to produce necessary records due to standard retention policies.

Arguments on the Stand

The petitioners, represented by Senior Advocate Sharan Jagtiani, argued that the action was not only "hopelessly time-barred" but also based on a technical fallacy. They demonstrated that the formulation Theophylline CR 300 mg was not included in the original ceiling price notifications that covered Theophylline SR 300 mg . By the time the government sought to include "CR" formulations in its price regime in 2006, the product was already off the market. Crucially, the company had destroyed the relevant records after its mandatory five-year retention period, leaving them defenseless against the stale claims.

Conversely, the Union of India , led by Senior Advocate A. S. Khandeparkar, insisted that the public interest involved in drug price control allowed for the retrospective application of ceiling prices, regardless of the delay. They argued that the company was under a statutory obligation to approach the government for price fixation, and the delay in service of notice did not nullify the underlying overcharging liability.

Legal Analysis and The "Reasonable Time" Doctrine

The bench, comprising Justice Manish Pitale and Justice Shreeram V. Shirsat, rejected the state's stance. The court emphasized that while statutory silence on limitation does not grant the executive infinite time to act, administrative fairness demands that authorities initiate proceedings within a "reasonable period."

The court drew a sharp distinction between "administrative" and "quasi-judicial" functions, noting that the blurred lines between these roles do not excuse the government from the duty of acting fairly. By failing to explain the decade-long slumber, the respondents severely prejudiced the petitioner’s ability to mount a defense.

Key Observations

Highlighting the gravity of regulatory accountability, the Court observed:

• "Such delayed action amounts to violation of principles of natural justice, as even under statutory provisions, the authorities are expected to initiate action within a reasonable period of time."
• "The contention of respondent No.1 that sustain release (SR) ought to be treated as equivalent to control release (CR), is unacceptable, for the reason that if that was the case, there was no necessity for issuing notification dated 03.10.2006 specifically including Theophylline CR 300 mg under the regime of ceiling price fixation."
• "We find substance in the contention raised on behalf of the petitioners that the respondents could not be permitted to rise from their slumber after more than a decade, to allege overcharging."

Final Decision

The High Court allowed the writ petition, quashing the demand notice dated 15.02.2016 and the subsequent recovery notice dated 30.10.2017.

This judgment serves as a vital precedent for corporate entities, reinforcing that regulatory authorities are not exempt from the norms of fair play. The ruling reinforces that the passage of time—when coupled with the destruction of records under established business practices—creates an insurmountable barrier to equitable enforcement. It effectively serves as a warning against "sleeping" on the exercise of statutory powers.